IL6 and inflammatory bowel disease: However, in contrast to Ozanimod and Siponimod, Etrasimod did not elevate IL-6 levels, which may be favorable under inflammatory disease conditions, since IL-6 signaling and subsequent T cell activation have been implicated in IBD pathogenesis (Atreya et al., 2000; Yamamoto et al., 2000), and therefore not further increasing IL-6 levels would be preferable.